ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Epilepsia

Epilepsia

Volume 41 Issue 5, Pages 624 - 627

Published Online: 2 Aug 2005

© 2010 International League Against Epilepsy



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: PDF (Size: 389K)  | Related Articles | Citation Tracking

Methsuximide Lowers Lamotrigine Blood Levels: A Pharmacokinetic Antiepileptic Drug Interaction
F. M. C. Besag 1 , D. J. Berry*, F. Pool 1
  1 St. Piers Lingfield, Surrey, London, England   *Medical Toxicology Unit, Guy's and St. Thomas', Trust, London, England
 Address correspondence and reprint requests to Dr. F. M. C. Besag at St. Piers Lingfield, St. Piers Lane, Lingfield, Surrey, RH7 6PW, U.K. E-mail: FBesag@aol.coms
Copyright 2000 International League Against Epilepsy
KEYWORDS
Methsuximide • Lamotrigine • Pharmacokinetic • Interaction • Levels

ABSTRACT

Summary: Purpose: To determine whether methsuximide (MSM) affects lamotrigine (LTG) blood levels and whether any change is of clinical significance.

Methods: LTG serum levels in 16 patients taking MSM were compared with those before starting or after stopping the MSM. The 16 patients, (11 boys, five girls) were young people (mean age, 15.5 years; range, 9–19 years) with a variety of seizure types and syndromes. In six cases, LTG levels were available both before MSM was started and after it was stopped.

Results: The mean LTG serum concentration before starting or after stopping MSM was 13.4 mg/L, and the mean level while taking MSM was 6.3 mg/L. This difference was highly significant (p < 0.0005, paired t test). MSM lowered the LTG serum concentration in every case, with a mean decrease of 53% (range, 36–72%). In some patients this led to a deterioration in seizure control when MSM was added or an improvement in seizure control after MSM was stopped.

Conclusions: Although MSM is a valuable add-on, broad-spectrum drug when used in combination with LTG, adjustment of the LTG dose may be necessary when MSM is started or stopped, to allow for the fact that MSM lowers LTG blood levels.


Accepted December 7, 1999

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1528-1157.2000.tb00218.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member

Latest News & Information
EPI Impact Factor

Sign Up Now
Sign Up Now
Sign-up for Content Alerts
Latest News & Information

Sign up for the Neurology NewsWire.

Neuro Newsletter

Get 6 free issues of breaking news and research delivered to your inbox each year!

Sign Up Now
Wiley Medical Twitter